Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1711-1716

  Clay, Jennifer ^a   Kulasekararaj, Austin G ^a   Potter, Victoria ^a   Grimaldi, Francesco ^a   McLornan, Donal ^a   Raj, Kavita ^a   de Lavallade, Hugues ^a   Kenyon, Michelle ^a   Pagliuca, Antonio ^a   Mufti, Ghulam J ^a,b   Marsh, Judith C W ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aplastic anemia; Haploidentical; HSCT; Nonmyeloablative; Stem cell transplant

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIBODY; RITUXIMAB;

ADULT; APLASTIC ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; PILOT STUDY; PLASMAPHERESIS; REDUCED INTENSITY CONDITIONING; SEVERE APLASTIC ANEMIA; ALLOTRANSPLANTATION; ANEMIA, APLASTIC; ANEMIA, REFRACTORY; COHORT ANALYSIS; DONOR; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; ANEMIA, APLASTIC; ANEMIA, REFRACTORY; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84908068047     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.028     Document Type: Article

References (31)

1. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. NEngl J Med 1993, 329:1152-1157.
2. Rosenfeld S., Follmann D., Nunez O., Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003, 289:1130-1135.
3. Scheinberg P., Cooper J.N., Sloand E.M., et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010, 304:1358-1364.
4. Socie G., Mary J.-Y., Schrezenmeier H., et al. Granulocyte colony stimulating factor for severe aplastic anaemia: A survey by the European Group for Blood and Marrow Transplantation. Blood 2007, 109:2794-2796.
5. Kojima S., Ohara A., Tsuchida M., et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002, 100:786-790.
6. Yamamoto H., Kato D., Uchida N., et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood 2011, 117:3240-3242.
7. + cells improved transplant outcome for patients with severe aplastic anemia undergoing cord blood transplantation. Blood (ASH Annual Meeting Abstracts) 2011, 118:654a.
8. Ciceri F., Lupo-Stanghellini M.T., Korthof E.T. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant 2013, 48:183-185.
9. Xu L.P., Liu K.Y., Liu D.H., et al. Anovel protocol for haploidentical hematopoietic SCT without invitro T cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012, 47:1507-1512.
10. Im H.J., Koh K.N., Choi E.S., et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2013, 19:754-759.
11. Brodsky R.A., Luznik L., Bolaños-Meade J., et al. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 2008, 42:523-527.
12. Gao L., Li Y., Zhang Y., et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without invitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive care. Bone Marrow Transplant 2014, 49:519-524.
13. Peffault de Latour R., Purtill D., Ruggeri A., et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2011, 17:78-85.
14. Yoshimi A., Kojima S., Taniguchi S., et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 2008, 14:1057-1063. for the Japan Cord Blood Bank Network (JCBBN).
15. Reisner Y., Hagin D., Martelli M.F. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011, 118:6006-6017.
16. Ciurea S., Champlin R. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant 2013, 19:180-184.
17. Brodsky R.A., Chen A.R., Dorr D., et al. High-dose cyclophosphamide forsevere aplastic anaemia: long-term follow-up. Blood 2010, 115:2136-2141.
18. Dezern A.E., Luznik L., Fuchs E.J., et al. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anaemia. Bone Marrow Transplant 2011, 46:1012-1013.
19. Bolanos-Meade J., Fuchs E.J., Luznik L., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012, 120:4285-4291.
20. Raj K., Pagluica A., Bradstock K., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014, 20:890-895.
21. Marsh J.C., Gupta V., Lim Z., et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011, 118:2351-2357.
22. Lim Z.Y., Pearce L., Ho A.Y., et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007, 138:517-526.
23. Fuchs E.J., Luznik L., Bolanos-Meade J., et al. Successful pregnancy and childbirth after reduced intensity conditioning and partially HLAmismatched bone marrow transplantation. Bone Marrow Transplant 2009, 43:969-970.
24. McCann S.R., Bacigalupo A., Gluckman E., et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European bone marrow transplant group. Bone Marrow Transplant 1994, 13:233-237.
25. Quillen K., Wong E., Scheinberg P., et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009, 94:1661-1668.
26. Killick S., Win N., Marsh J., et al. Pilot study of HLA alloimmunisation after transfusion with pre-storage leucocyte depleted blood products in aplastic anaemia. Br J Haematol 1997, 97:677-684.
27. Pavenski K., Freedman J., Semple J.W. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012, 79:237-245.
28. Ciurea S.O., Thall P.F., Wang X., et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011, 118:5957-5964.
29. Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell-depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1833-1844.
30. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as riskfactors in recipients after transplantation of bone marrow fromunrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
31. Castagna L., Crocchiolo R., Furst S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantationwith a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014, 20:724-772.